Cysteine modification reveals which subunits form the ligand binding site in human heteromeric 5-HT3AB receptors

Journal of Physiology

Volumn 589, Issue 17, 2011, Pages 4243-4257

  Thompson, A J ^a   Price, K L ^a   Lummis, S C R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; METHANETHIOSULFONATE ETHYLAMMONIUM; MUTANT PROTEIN; SEROTONIN 3A RECEPTOR; SEROTONIN 3B RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; THIOL REAGENT; UNCLASSIFIED DRUG; CARRIER PROTEIN; LIGAND; SEROTONIN 3 RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING SITE; DISULFIDE BOND; LIGAND BINDING; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; RECEPTOR BINDING; RESIDUE ANALYSIS; XENOPUS; GENETICS; HUMAN; METABOLISM;

BINDING SITES; CARRIER PROTEINS; CYSTEINE; HUMANS; LIGANDS; RECEPTORS, SEROTONIN, 5-HT3;

EID: 80052248559     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2011.208439     Document Type: Article

References (50)

1. 3 receptors. Proc Natl Acad Sci U S A 102, 12595-12600.
2. 3 receptor revealed by unnatural amino acid mutagenesis. J Neurosci 24, 9097-9104.
3. Bhattacharya A, Dang H, Zhu QM, Schnegelsberg B, Rozengurt N, Cain G, Prantil R, Vorp DA, Guy N, Julius D, Ford AP, Lester HA & Cockayne DA (2004). Uropathic observations in mice expressing a constitutively active point mutation in the 5-HT3A receptor subunit. J Neurosci 24, 5537-5548.
4. A receptor: evidence for a β-strand. J Neurosci 19, 4847-4854.
5. 3 receptors: the role of oligomerization and chaperone proteins. Mol Cell Neurosci 21, 38-50.
6. Brady CA, Stanford IM, Ali ILL, Williams JM, Dubin AE, Hope AG & Barnes NM (2001). Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology 41, 282-284.
7. Brams M, Gay EA, Saez JC, Guskov A, Van Elk R, Van Der Schors RC, Peigneur S, Tytgat J, Strelkov SV, Smit AB, Yakel JL & Ulens C (2011). Crystal structures of a cysteine-modified mutant in loop D of acetylcholine-binding protein. J Biol Chem 286, 4420-4428.
8. Chen JG, Liu-Chen S & Rudnick G (1998). Determination of external loop topology in the serotonin transporter by site-directed chemical labeling. J Biol Chem 273, 12675-12681.
9. Collingridge GL, Olsen RW, Peters J & Spedding M (2009). A nomenclature for ligand-gated ion channels. Neuropharmacology 56, 2-5.
10. Das P & Dillon GH (2003). The 5-HT3B subunit confers reduced sensitivity to picrotoxin when co-expressed with the 5-HT3A receptor. Brain Res Mol Brain Res 119, 207-212.
11. Das P & Dillon GH (2005). Molecular determinants of picrotoxin inhibition of 5-hydroxytryptamine type 3 receptors. J Pharmacol Exp Ther 314, 320-328.
12. Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG & Kirkness EF (1999). The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 397, 359-363.
13. Dubin AE, Huvar RD, Andrea MR, Pyati J, Zhu JY, Joy KC, Wilson SJ, Galindo JE, Glass CA, Luo L, Jackson MR, Lovenberg TW & Erlander MG (1999). The pharmacological and functional characteristics of the serotonin 5-HT3A receptor are specifically modified by a 5-HT3B receptor subunit. J Biol Chem 274, 30799-30810.
14. Exley R, Moroni M, Sasdelli F, Houlihan LM, Lukas RJ, Sher E, Zwart R & Bermudez I (2006). Chaperone protein 14-3-3 and protein kinase A increase the relative abundance of low agonist sensitivity human α4β2 nicotinic acetylcholine receptors in Xenopus oocytes. J Neurochem 98, 876-885.
15. Gleitsman KR, Kedrowski SM, Lester HA & Dougherty DA (2008). An intersubunit hydrogen bond in the nicotinic acetylcholine receptor that contributes to channel gating. J Biol Chem 283, 35638-35643.
16. Goldin AR (1992). Maintenance of Xenopus laevis and oocyte injection. Methods Enzymol 207, 267-279.
17. Hansen SB, Sulzenbacher G, Huxford T, Marchot P, Taylor P & Bourne Y (2005). Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations. EMBO J 24, 3635-3646.
18. 3 receptor. Biophys J 84, 1720-1733.
19. Hilf RJ & Dutzler R (2008). X-ray structure of a prokaryotic pentameric ligand-gated ion channel. Nature 452, 375-379.
20. Holbrook JD, Gill CH, Zebda N, Spencer JP, Leyland R, Rance KH, Trinh H, Balmer G, Kelly FM, Yusaf SP, Courtenay N, Luck J, Rhodes A, Modha S, Moore SE, Sanger GJ & Gunthorpe MJ (2009). Characterisation of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function. J Neurochem 108, 384-396.
21. 3 receptor. J Biol Chem 283, 6826-6831.
22. 3 receptors. Nature 424, 321-324.
23. 3AB receptor. Biophys J 98, 1494-1502.
24. Mukhtasimova N, Lee WY, Wang HL & Sine SM (2009). Detection and trapping of intermediate states priming nicotinic receptor channel opening. Nature 459, 451-454.
25. Nelson ME, Kuryatov A, Choi CH, Zhou Y & Lindstrom J (2003). Alternate stoichiometries of α4β2 nicotinic acetylcholine receptors. Mol Pharmacol 63, 332-341.
26. Price KL, Bower KS, Thompson AJ, Lester HA, Dougherty DA & Lummis SC (2008). A hydrogen bond in loop A is critical for the binding and function of the 5-HT3 receptor. Biochemistry 47, 6370-6377.
27. 3 receptor. J Biol Chem 279, 23294-23301.
28. Rayes D, De Rosa MJ, Sine SM & Bouzat C (2009). Number and locations of agonist binding sites required to activate homomeric Cys-loop receptors. J Neurosci 29, 6022-6032.
29. 3 receptor: a model ligand-gated ion channel (review). Mol Membr Biol 19, 11-26.
30. 3 receptor agonist-binding residues using homology modeling. Biophys J 84, 2338-2344.
31. C receptor agonist binding pocket. Constructing a complete model. J Biol Chem 280, 1535-1542.
32. 3 receptor ligand binding domain. J Biol Chem 275, 5620-5625.
33. Sullivan DA & Cohen JB (2000). Mapping the agonist binding site of the nicotinic acetylcholine receptor. Orientation requirements for activation by covalent agonist. J Biol Chem 275, 12651-12660.
34. 3 receptor. Mol Membr Biol 23, 442-451.
35. 3 receptor at a location that overlaps the picrotoxin binding site. Neuropharmacology 60, 488-495.
36. 3 receptors. Br J Pharmacol 151, 666-677.
37. 3 receptors. Curr Pharm Des 12, 3615-3630.
38. 3 receptor as a therapeutic target. Expert Opin Ther Targets 11, 527-540.
39. 3 receptor binding site using modeling and radioligand binding. J Biol Chem 280, 20476-20482.
40. Thompson AJ, Lester HA & Lummis SCR (2010b). The structural basis of function in Cys-loop receptors. Q Rev Biophys 43, 449-499.
41. 3 receptor. Biophys J 95, 5728-5736.
42. 3 receptor. Mol Pharmacol 80, 183-190.
43. Tremblay PB, Kaiser R, Sezer O, Rosler N, Schelenz C, Possinger K, Roots I & Brockmoller J (2003). Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 21, 2147-2155.
44. Venkataraman P, Venkatachalan SP, Joshi PR, Muthalagi M & Schulte MK (2002). Identification of critical residues in loop E in the 5-HT3ASR binding site. BMC Biochem 3, 15.
45. 3A) receptors despite direct interactions with 5-HT3A, -C, -D, and -E subunits. J Biol Chem 285, 26956-26965.
46. Ward WH, Timms D & Fersht AR (1990). Protein engineering and the study of structure-function relationships in receptors. Trends Pharmacol Sci 11, 280-284.
47. 3 receptor function. J Physiol 588, 603-616
48. 3 receptor onto d-tubocurarine structure. Mol Pharmacol 70, 571-578.
49. 3 receptor. J Biol Chem 274, 5537-5541.
50. Zwart R & Vijverberg HP (1998). Four pharmacologically distinct subtypes of α4β2 nicotinic acetylcholine receptor expressed in Xenopus laevis oocytes. Mol Pharmacol 54, 1124-1131.